<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rosas-Salazar C</submitter><funding>NICHD NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>NEI NIH HHS</funding><funding>NHLBI</funding><funding>NCRR NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIAID</funding><funding>NIGMS NIH HHS</funding><funding>NIH HHS</funding><funding>NIGMS</funding><pagination>966-976</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9036861</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>149(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The risk factors determining short- and long-term morbidity following acute respiratory infection (ARI) due to respiratory syncytial virus (RSV) in infancy remain poorly understood.&lt;h4>Objectives&lt;/h4>Our aim was to examine the associations of the upper respiratory tract (URT) microbiome during RSV ARI in infancy with the acute local immune response and short- and long-term clinical outcomes.&lt;h4>Methods&lt;/h4>We characterized the URT microbiome by 16S ribosomal RNA sequencing and assessed the acute local immune response by measuring 53 immune mediators with high-throughput immunoassays in 357 RSV-infected infants. Our short- and long-term clinical outcomes included several markers of disease severity and the number of wheezing episodes in the fourth year of life, respective</pubmed_abstract><journal>The Journal of allergy and clinical immunology</journal><pubmed_title>Upper respiratory tract bacterial-immune interactions during respiratory syncytial virus infection in infancy.</pubmed_title><pmcid>PMC9036861</pmcid><funding_grant_id>KL2 TR000446</funding_grant_id><funding_grant_id>R21 AI142321</funding_grant_id><funding_grant_id>UL1 TR000445</funding_grant_id><funding_grant_id>P30 EY008126</funding_grant_id><funding_grant_id>K24 AI077930</funding_grant_id><funding_grant_id>K01 HL149989</funding_grant_id><funding_grant_id>R01 GM140464</funding_grant_id><funding_grant_id>UG3 OD023282</funding_grant_id><funding_grant_id>U19 AI095227</funding_grant_id><funding_grant_id>P30 CA068485</funding_grant_id><funding_grant_id>R01 HL146401</funding_grant_id><funding_grant_id>UL1 RR024975</funding_grant_id><funding_grant_id>K23 HL148638</funding_grant_id><funding_grant_id>G20 RR030956</funding_grant_id><funding_grant_id>K12 HD087023</funding_grant_id><funding_grant_id>R21 AI149262</funding_grant_id><funding_grant_id>HHSN272200900007C</funding_grant_id><funding_grant_id>R21 AI154016</funding_grant_id><funding_grant_id>U19 AI110819</funding_grant_id><pubmed_authors>Turi KN</pubmed_authors><pubmed_authors>Peebles RS</pubmed_authors><pubmed_authors>Chappell JD</pubmed_authors><pubmed_authors>Wiggins DA</pubmed_authors><pubmed_authors>Tang ZZ</pubmed_authors><pubmed_authors>Gebretsadik T</pubmed_authors><pubmed_authors>Anderson LJ</pubmed_authors><pubmed_authors>Hartert TV</pubmed_authors><pubmed_authors>Rosas-Salazar C</pubmed_authors><pubmed_authors>Das SR</pubmed_authors><pubmed_authors>Hong Q</pubmed_authors><pubmed_authors>Shilts MH</pubmed_authors><pubmed_authors>Lynch CE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Upper respiratory tract bacterial-immune interactions during respiratory syncytial virus infection in infancy.</name><description>&lt;h4>Background&lt;/h4>The risk factors determining short- and long-term morbidity following acute respiratory infection (ARI) due to respiratory syncytial virus (RSV) in infancy remain poorly understood.&lt;h4>Objectives&lt;/h4>Our aim was to examine the associations of the upper respiratory tract (URT) microbiome during RSV ARI in infancy with the acute local immune response and short- and long-term clinical outcomes.&lt;h4>Methods&lt;/h4>We characterized the URT microbiome by 16S ribosomal RNA sequencing and assessed the acute local immune response by measuring 53 immune mediators with high-throughput immunoassays in 357 RSV-infected infants. Our short- and long-term clinical outcomes included several markers of disease severity and the number of wheezing episodes in the fourth year of life, respective</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T08:53:10.102Z</modification><creation>2025-04-04T08:53:10.102Z</creation></dates><accession>S-EPMC9036861</accession><cross_references><pubmed>34534566</pubmed><doi>10.1016/j.jaci.2021.08.022</doi></cross_references></HashMap>